-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NcMDHIlC8GpMlg0XSaBez/r4SiWDCLJObb7K8cuK/3Y6coRr08N5GuCmuFGKYk4A
 cYNWtaLqY/xg3XGa+5vcXw==

<SEC-DOCUMENT>0001193125-10-167178.txt : 20100727
<SEC-HEADER>0001193125-10-167178.hdr.sgml : 20100727
<ACCEPTANCE-DATETIME>20100727135415
ACCESSION NUMBER:		0001193125-10-167178
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100726
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100727
DATE AS OF CHANGE:		20100727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27436
		FILM NUMBER:		10971185

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		4152444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE
COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): July&nbsp;26, 2010 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Titan Pharmaceuticals, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of incorporation) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-27436</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-3171940</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>400 Oyster Point Blvd., Suite 505, South San Francisco, CA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94080</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: 650-244-4990 </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, is Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any
of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
July&nbsp;26, 2010, Titan Pharmaceuticals, Inc. (the &#147;Company&#148;) issued a press release announcing the receipt of a grant under the Small Business Innovation Research (SBIR) program supporting the development of a long-term, non-fluctuating
dopamine agonist treatment for Parkinson&#146;s disease. The first year award in the amount of $300,000 will be available to the Company starting August&nbsp;1, 2010, and an additional $195,000 for the second year starting August&nbsp;1, 2011 has
been recommended subject to availability of funds and satisfactory progress of the project. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated July&nbsp;26, 2010</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TITAN PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>UNIL</SMALL>
B<SMALL>HONSLE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Sunil Bhonsle</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>President</B></FONT></TD></TR></TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated:
July&nbsp;27, 2010 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit Index </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated July 26, 2010</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR>
<TD VALIGN="top">


<IMG SRC="g47763g91p53.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Titan Pharmaceuticals, Inc.</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE
RELEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TITAN RECEIVES SBIR GRANT TO INVESTIGATE LONG TERM </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TREATMENT FOR PARKINSONS DISEASE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>South San Francisco, CA &#150; July&nbsp;26, 2010</B> &#150; Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that the National Institutes of
Health (NIH) has awarded the company a grant under the Small Business Innovation Research (SBIR) program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson&#146;s disease. The first year award in the
amount of $300,000 will be available to Titan starting August&nbsp;1, 2010, and an additional $195,000 for the second year starting August&nbsp;1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project.
The grant will be administered by the National Institute of Neurological Disorders and Stroke (NINDS). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parkinson&#146;s disease (PD) is a
progressive disorder associated with a loss of dopamine producing neurons in the brain. The cornerstone of symptomatic treatment for PD is dopamine replacement therapy, and dopamine agonists such as pramipexole, ropinirole, apomorphine, and lisuride
play a key part in the treatment of early as well as advanced stages of the disease. There is increasing evidence that maintaining continuous and stable blood levels of the dopamine agonists may minimize the motor fluctuations and dyskinesias
(involuntary movements) that are a debilitating side effect of the frequent oral administration of current dopamine replacement therapies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Titan&#146;s ProNeura technology can be used to develop a subcutaneous implant that provides round-the-clock delivery of dopamine agonists while
maintaining a stable, non-fluctuating plasma drug level for 6 months or longer following a single treatment. The SBIR grant will cover all the external expenses for the initial evaluation of the non-clinical safety and efficacy of implant
formulations of select dopamine agonists that are currently marketed for the treatment of PD. These studies will take approximately two years to complete and the data will provide a basis for further development of potential product candidates that
may alleviate the &#145;on/off&#146; motor fluctuations and treatment-related dyskinesias associated with current dopamine-replacement treatment regimens. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are very pleased by the award of this SBIR grant&#148; said Sunil Bhonsle, President of Titan. &#147;Long term, non-fluctuating drug delivery
using our ProNeura technology has been initially established with Probuphine&reg; which is currently in Phase 3 clinical development for the treatment of opiate addiction, and this SBIR grant gives us an opportunity to investigate expanding the use
of this technology&#148; he noted. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Parkinson&#146;s disease is a progressively debilitating condition and this support from NINDS will
help us evaluate the possibility of alleviating some side-effects of current treatments, and hopefully make a meaningful difference for these patients&#148; said Marc Rubin, M.D., Executive Chairman of Titan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are over 1.5&nbsp;million PD patients in the US, with about 50,000 new patients each year. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Titan Pharmaceuticals </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For
information concerning Titan Pharmaceuticals, Inc., please visit the Company&#146;s website at www.titanpharm.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The press release may
contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating
to the Company&#146;s development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in
development, testing, regulatory approval, production and marketing of the Company&#146;s drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug candidates that could slow or prevent product development
or commercialization, the uncertainty of patent protection for the Company&#146;s intellectual property or trade secrets, and the Company&#146;s ability to obtain additional financing. Such statements are based on management&#146;s current
expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONTACT: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Titan Pharmaceuticals, Inc.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sunil Bhonsle, 650-244-4990 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"># # # </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g47763g91p53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g47763g91p53.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`<`!X`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=5B?S?ODWV]\0_@UV!WCT
M;FL9M_L3;^ZNN<7C,GE\#C-R445%N+>.+P^5C?%9>&>AE>:AJG56924)N.1[
M8N&=$K&0&U`9%>)_+K)+[IWMORI[L>]5AR5SI#)/L%Q;73NB2/$Q:*!W0ZXR
M&%&`)`.>!ZT^O^@AG^:'_P`_9V!_Z)KK[_ZT>V]5Q_$G^\G_`*"ZZV?\`%]V
MK_HUWW_9?=_];>O?]!#/\T/_`)^SL#_T377W_P!:/?M5Q_$G^\G_`*"Z]_P`
M7W:O^C7??]E]W_UMZ]_T$,_S0_\`G[.P/_1-=??_`%H]^U7'\2?[R?\`H+KW
M_`!?=J_Z-=]_V7W?_6WKW_00S_-#_P"?L[`_]$UU]_\`6CW[5<?Q)_O)_P"@
MNO?\`%]VK_HUWW_9?=_];>O?]!#/\T/_`)^SL#_T377W_P!:/?M5Q_$G^\G_
M`*"Z]_P`7W:O^C7??]E]W_UMZ]_T$,_S0_\`G[.P/_1-=??_`%H]^U7'\2?[
MR?\`H+KW_`!?=J_Z-=]_V7W?_6WKW_00S_-#_P"?L[`_]$UU]_\`6CW[5<?Q
M)_O)_P"@NO?\`%]VK_HUWW_9?=_];>O?]!#/\T/_`)^SL#_T377W_P!:/?M5
MQ_$G^\G_`*"Z]_P`7W:O^C7??]E]W_UMZ]_T$,_S0_\`G[.P/_1-=??_`%H]
M^U7'\2?[R?\`H+KW_`!?=J_Z-=]_V7W?_6WJVC^4=\\/YM/\P3OJD;<'9&R:
M/XY=8Y3&9/N?<3=/[2QG\:I)"T]-UYM?+4.!L=T9]47S%)HI*&A9JB^OPK)I
M7N7E"AE\,?$=)_8#J.?,_+[<8I_>M]C_`+J_L+R0R[?M]V_N#N4;I81?77#^
M&PP;J9&E_L8C\-5822`1TIJ*CW_-@_X4I=0?RI?E3%\6M\_&#LGMS,R]8;/[
M-7=NU-];7V]C!2;NK]QT$.*..R^*K*O[BB;;S,TFO2_E``&FY6=<K>JS_P#H
M-^^-W_>"7=__`*-;8?\`]8??NO=>_P"@W[XW?]X)=W_^C6V'_P#6'W[KW7O^
M@W[XW?\`>"7=_P#Z-;8?_P!8??NO=%=^8W_"L?X2_-[HC<7QZ[9^%'R@P>R]
MRY7;>8KLCL3N;J[&;CBJMK9JDSN/2FJLSLG.T"P2U5&JRAJ=BR$@%3S[;EC$
MJ:"2,@U'''V@]29[1^ZG,/LSSQ;\^\KQ6DV[VT4T:I<*[1%9HVC:HC>-J@-5
M:-QX@]4V_P##@_\`)T_[QA_F*_\`I1/QZ_\`M'^V?I1_OR3]H_S=9??\G)_?
M+_HV\M_\X+O_`+:^O?\`#@_\G3_O&'^8K_Z43\>O_M'^_?2C_?DG[1_FZ]_R
M<G]\O^C;RW_S@N_^VOKW_#@_\G3_`+QA_F*_^E$_'K_[1_OWTH_WY)^T?YNO
M?\G)_?+_`*-O+?\`S@N_^VOKW_#@_P#)T_[QA_F*_P#I1/QZ_P#M'^_?2C_?
MDG[1_FZ]_P`G)_?+_HV\M_\`."[_`.VOKW_#@_\`)T_[QA_F*_\`I1/QZ_\`
MM'^_?2C_`'Y)^T?YNO?\G)_?+_HV\M_\X+O_`+:^O?\`#@_\G3_O&'^8K_Z4
M3\>O_M'^_?2C_?DG[1_FZ]_R<G]\O^C;RW_S@N_^VOJ31_/[^3M65=+1I\8_
MYBBO55,%,K'Y$?'HZ6GE2(-;_0@+V+WM<7_J/?OI1_OR3]H_S=>_Y.3^^7_1
MMY;_`.<%W_VU]#Y\\^A=E_&/Y:=Q]&]=Y#<>4V7L3+X6EV_6[MJ:"LW'+19;
M:V#S]LK58N@QE!/41395DU101*54<7Y]T2H9HZDA32IXG`.>NLGL#[@;Q[I^
MT.R<_;_'!%N^Y6IDD2$,(E(D=*('9V`HHXL<](?XL_&7L_Y?=Y;%Z%ZEQ4M?
MN?>>4B@J<DU+4U&)VEM^*1&S>\-QRTR,:/!8&B8RRNQ7R/HB0F21%/I"^$C_
M`+1N'R^9^0_GPZ$/NA[D\M>TO)-[SQS3*(]NLXB52JAYY2#X<$0/Q22MVJ!6
M@JQ[5)'TV/A_\4NL/A?T'LCH3JK&K383;%']QFLO*I.3W?N^O2*3<F[LS,[2
M22U^9KE+!2Q6GIUC@CM'$@"J.,1($7_BSZ]?-Q[L^Z',OO!SU>\\\T2%KVY>
MD<8^""!21%!&,`+&N":5=BSM5F)Z^:A_PL7_`.WO%%_XJATM_P"]%V9[OU&_
M6JE[]U[KWOW7NO>_=>Z][]U[KWOW7NK%,)_**_FB;DPN(W'@/@!\M,S@=P8O
M'YO"9?'=';]JL?EL/E:2&OQF3H*J+#-%4T5?15"2Q2*2KQN""0??NO?9TY_\
M,X?S6O\`O7=\P?\`T0_8/_UD][H>O9]#^P]>_P"&</YK7_>N[Y@_^B'[!_\`
MK)[]0]>SZ']AZ]_PSA_-:_[UW?,'_P!$/V#_`/63WZAZ]GT/[#U[_AG#^:U_
MWKN^8/\`Z(?L'_ZR>_4/7L^A_8>G+#_R=OYJ\&7Q4\O\O#Y@+'#DJ"21CT1V
M``J)51,S%FPH50`.22`/R;>_4/7OR/[#UL`_S:L)F,O_`#,?D)MG%XRMR.X<
MGO#86!QV%HX'GR5=FZW8>R\=1XFEI8PTDU?4Y"184C`+-(P7Z^R]G$<DK'^(
M?G@4'Y]?17]T.\M=N^Z[RQ?7SK%9P;7(\CL=*HB2S,S,3@!5!))X`9ZW(_Y-
M?\L;&?`3I-]T[\I<?DODGV]C,?D.P\O'36EV5@)HJ3(8[JO&U,C.[0X:J02Y
M.5-*5614D:HX86]OP1%:R/\`VK4K\AY`?9Y^IJ>N2?WO/O)77OMSG^[=D:2/
MV\VJ1EM8RV+B4%D:]<<*R+40@U*1'-&=QU<W[4=8@=?*T_X6+_\`;WBB_P#%
M4.EO_>B[,]^Z]UJI>_=>Z][]U[KWOW7NO>_=>Z][]U[K<'^?/8_8."^1M=08
MGL'>^&Q5'TS\9FAH<=O#<./QU%$/C7U1++X*2ER45+2PCU.P156Y)^I/LK:"
M*6>1I`2:CS(_"/0CKZ$?N=[#R[<_=KY9O=QLK)Y/HIF>22&(FBW$Y+.Q6IHH
MR2<`?+H#_B=M_P"3/S)W;#B=A=L=B;2V4V02E3>5=NO=.1R6:A28(]5A<9-F
M(J6CQ\_.B6H#R.OJ"*+$N+M\!'<#_O3?Y^L,_?#[]^R6F[W/+?LCL&SO8V\I
M0[I=VZ2"8J:,UK;!5"Q$X628EF`J(U!!.T]UM_PG0W#N?K6CSF8_F"?)+%;S
MR6/\U$M1)3YK;T508W$;Y"@I\K@<A+`TK`LD-7"]E%F'(-FVZU(P&!]=3?Y3
M3K'CE/[[/O#L&X_5;_#L6^6!(K!<[=:PBF:Z)+6*)U)!P6U@$#MXUUJOF1U-
M\H?A)\@MY?'GM7M+?%7N';*T>2Q.X</OG>`P6\=IY96DP>Z\**K)K4Q4>01&
M22&4>6FJ(WB>^D,S/T4*G2X)/^F;_H+KKM]W[W6]IOO!\I-OW+VV65KO=HRI
M>V+Q1-+:NU=!U"-1)#*%+12A1J`*LJNK*"O?Z6NUO^?H=C_^AUNG_P"NWNWT
M=M_"?]Z;_H+J>_ZI<K?]&VP_YP1?]`]>_P!+7:W_`#]#L?\`]#K=/_UV]^^C
MMOX3_O3?]!=>_JERK_T;;#_G!%_T#UMI?R`OY8%7DY,7_,+^25!/G,KEHYI_
MCYMG=D=1DZPI((8V[GRL^2>62HJIZ=&IL"',FF)Y:L@-]JZNV\2FDE*1CX1_
MS]^?E7RZY4_?M^\I#;+)[!^W3K!9PD#=)H"$7S_Q!`E``"0]S2F0L7#Q0=N?
MVMZY3=>]^Z]UKP?S//\`A.#\5/YIWR8C^4'<O=7?6PMWQ=<;4ZU7`]<5.PHM
MN_PK:5=GZZCKBNY-GYW(_P`0J9-P2++^_P".T:Z5!O?W7NJ7_D3_`,)!_@QT
M[5_'NFPGR+^4N27M[Y);`Z9S;9.MZM8X[`;KP.],I79'&"FZ^IPN6AGVY"L3
M2^2)5=]4;$@CW7NC'_\`0%!_+\_[R>^7'_G=U'_]K;W[KW7O^@*#^7Y_WD]\
MN/\`SNZC_P#M;>_=>ZIE_GM?\)POBE_*P^#L'R?Z;[I[[W[O"7NG8'6IP78]
M3L*;;@Q.[,7NVNK:T)MS9^"R(R%/)M^,1'SF.SMJ4\$>Z]UIH^_=>ZV?/YOV
M1J<9V7O62EF:G>MZ@^)6'EF1BDD='E^@NFJ*M\;J05=Z65DO_1C[0IFX<?TA
M_P`='79"VYBW7EC^[47<MFD:&^DVOZ;6I(94N=Q:*4J1D,8V9:^C'JR[^4WN
M?:^R\/MGQBDIQ3PT8`C1%`5533PH%[`#_;>UW7&\``4'#K<YZU^8VSL3LNCA
MKZBFE^SI%\1+N"`L=[&WU6_^Q]^Z]UI>_P`_OOW;?;WRDZ9W#C)8),I.-Q;0
MJ6I4O))BI,7)D:2&9B59J:DJ\<KK>X0DV'/MN456OF#UFK]P'FV_Y<^\;M^T
M0/)^[MZL[FUGC6I5RL33PLPJ!^F\9HQ!*ZB`.[JEWVWUW[ZND_DQ?RR\M\[N
M]:7>G86#JE^,/4>7I,AV'D9T>*DWSN"F\-?C.L,=)>-JA<FI23+/&P:FH&M<
M/-'[:H9I-`_LU/<?7^C_`)_3AZ]8:_?#^\C;>R/)3;)R_,O^N1NL3+:J,M;1
M&JO>,,TT9$(([Y1_"C=?1&Q6*QF#QF/PV&Q]'B<1B:.FQV+Q>.IH:/'XZ@HX
M4IZ2BHJ2G2."FI::"-4CC10J*``+>UO7`"YN;F]N9+R\D>6[E<N[N2S.S&K,
MS&I)))))-2<GJ?[]TQU[W[KW7O?NO=$,^<__`!=/A!_XOGTO_P"\?VI[]U[H
M^?OW7NO>_=>ZU4O^%B__`&Z'HO\`Q:_I;_WG>S/?NO=?*T]^Z]UM4?S2-J1;
MX[JWGM6258&R_1GQFBI*EA=:3(P?&WJ2JQM4;<@05L*%K<Z;^T*5$\A'\0_X
MZ.N\GL9[>6GNO]QNP]O;MEC&Y[/<1QR'(CG6ZED@D/G1940M3.G53HB7Q<^7
M^8Z5R7]QM\L^`W+@GCI:NDJ->B98PIBJJ297\=12U$=G1T)!4C\^UH(/#KB-
MSOR/S1[<<T7?)G.5J]GS!92:)(VX'S5T8=KQNI#(ZD@J1U:-FOYK&.PFV9B=
MR01K'2MR9)1_8)^@E'%_Q[WT$R0!4\.JPZWLG=WR1[-_TT[F%3!MC%4==1[!
MBG:2&7+39/539/.O3.YD6ABIT,5.6`\C,S`6`):D-<#KK%_=Y?=[WRSW8^_'
M-<$EMMYM9(=I1C1I_&K'/=%.(A"`QQ%O[1F9@**"3O?#3XF]D?-CY";&^/W6
M4,4>5W-4M7[@SM4T:X_9^RL7+3ON?=N0#NAFAP]%,#'`EY*FH>*%1JD!]L.6
M)$<?]H?Y#S/^;Y]='O>+W7Y;]F.0KSGGF5_T(%TPQ#X[BX8'PH$^;L.YN"(&
M=L+U]-CXQ?&[K'XE=([%Z%ZDQ7\.V?L?%K21U-0E-_%]PY68^;+[FW#54T%.
MN0SV;K6:6>8K^0BV1$4*418T"+P'^K/SZ^;GW)]P^9/=3G.^YYYJE\3=KV74
M0"?#B082&($G3'&M%5:^I-6))'WW?H#=>]^Z]U[W[KW7O?NO=$,^<_\`Q=/A
M!_XOGTO_`.\?VI[]U[H^?OW7NO>_=>ZU4O\`A8O_`-NAZ+_Q:_I;_P!YWLSW
M[KW7RM/?NO=;;'\PG_LIS)?^(<^,7_P-?4_M"O\`;2?Z8?\`'1U]%?W+O_$:
M.5O^>27_`+29NJ]]W[!V?ORC2AW9@*'+Q0L'IYI%>GKZ9@"!]MD:5H:Z%>?T
MK($/Y!]O"H-1U,'N)[2^W'NQMJ[5[@[1:;E;(:HS@I-&17^SN(RDR#/PA])\
MU/2$PWQYZBP=;#D*?:OWM33NDE.,UE,IF*:%T)*L*.OJIJ1S<_VT8>_5;UZB
M3E;[FGW<.4-TCWG;.7(IK^)@R&ZFGND5AP(BFD:)O]NC#`Z,!MS;F9W1F\)M
M3:N&K,UG\]D<?@MO8##TC5%=DLGD)XZ+&XO'45.EY)JBHE6.-$`%R/H/='8(
MM3Q_PGK)&\O-MV/;9+Z]>&UVJUA+.QTQQ111K4G%%1$4<!0`"@ZW_P#^65_+
MCPO\OFA^-]%N"GHJ_P"0':M!V=N'N;<4+K5ICZB/:&*EQ/7^"JVIX)$P&UXI
MK2V!%5D3--J9/$$=AC*+J?\`M&X_YA\AU\\GWK_O#7WOWSZ9+)G3D/:W>/;X
MC5=0-!)=2+4CQ9J=O\$6E*!M9-\GM[K%GKWOW7NO>_=>Z][]U[KWOW7NB&?.
M?_BZ?"#_`,7SZ7_]X_M3W[KW1\_?NO=>]^Z]UJI?\+%_^W0]%_XM?TM_[SO9
MGOW7NOE:>_=>ZVV/YA/_`&4YDO\`Q#GQB_\`@:^I_:%?[:3_`$P_XZ.OHK^Y
M=_XC1RM_SR2_]I,W1)O;W64O71(`N>`/J?P/]?WHD**G`'6J@<>MTC_A/Y_*
MJ386#P'SM[]V^G]^=RT+U?Q\VCEJ6MIZS9>VZZGJZ&H[%RE)4&!!G-UT-2Z8
MR.2)_M\<PJ5;74)X]0J9#X["@_"#Y#U/S/\`(=<<?OX_>@;?[Z?V2Y%G/[DM
MGT[I.A4K<2J586J,*GPX64&8AAKE'AD4C.K8Q[#_`.9]?'7_`)8=P_\`O*8C
MVJZY?=&!]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1#/G/_P`73X0?^+Y]+_\`O']J
M>_=>Z/G[]U[KWOW7NM5+_A8O_P!NAZ+_`,6OZ6_]YWLSW[KW7RM/?NO=;;'\
MPG_LIS)?^(<^,7_P-?4_M"O]M)_IA_QT=?17]R[_`,1HY6_YY)?^TF;HDWM[
MK*7J^/\`D>_ROJOYI]Q0]V]K8ET^-72V?HJK)TM;!60Q]J;YI5-;B=F8V=3!
M'/A,/41Q5>:D5W7QB.D9?\I9HV@OCOI_T)3GYD>7V#S^>/7K!C[ZGWEXO9_E
M(\E\K2@^XF\0,J,I4FRMSVO<.,D2."R6X(!U:I0?TP&^@C!!#30Q4]/#%3T]
M/%'!!!!&L4,,,2".*&&)`J111HH"JH``%A[6]<&'=Y',DA+2,222:DDY))/$
MGS/GT`?8?_,^OCK_`,L.X?\`WE,1[]U7HP/OW7NO>_=>Z][]U[KWOW7NO>_=
M>Z(9\Y_^+I\(/_%\^E__`'C^U/?NO='S]^Z]U[W[KW6JE_PL7_[=#T7_`(M?
MTM_[SO9GOW7NOE:>_=>ZVV/YA/\`V4YDO_$.?&+_`.!KZG]H5_MI/],/^.CK
MZ*_N7?\`B-'*W_/)+_VDS=0O@?\`"CLWYY_(3;'2'7D%30XV5ES/8F^30O68
MGKS8]+*JY'<.4`DA1YYY&6EH8-8>IK)D0>D.R[=F9A%'_:'S]!Z_Y!\_LZD'
MWS]YN6_8WD*YYQWYE>Z`\.TMM05[JX8=D2<30"KR-2B1JQXT!^F-\>^@NL/C
M#T_LCI#I_;E+MG8FQ<1#C,;1PJ#5U]5;R9+/9JL:\^3SV<K6>IJZF4M)--(2
M3:P"M55%TKP'7SA\^\]<R>Y/-E[SIS9<-<[W>REW8_"H_!'&O!(XUHB(M`J@
M>=>AG]VZ!_1?NP_^9]?'7_EAW#_[RF(]^Z]T8'W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=$,^<_\`Q=/A!_XOGTO_`.\?VI[]U[H^?OW7NO>_=>ZU4O\`A8O_`-NA
MZ+_Q:_I;_P!YWLSW[KW7RM/?NO=;@_S)V!O+M3YJ8;K;KS;V0W9OG?'7/Q2V
MUM7;>*B\V0S&:RGQQZEIZ.BIU)5%+NUV=RJ1H"[$*I(+B^B63S8L`!ZG2,=?
M0G]TW?\`9^5ONF[!S%S!<1VNRV6W7$LTKFBI&EQ.68_EP`J2:``D@=;X/\KC
M^7=LO^7K\>\;LZ.''9GN7>L&/S_=&_(:>+[C+[B,!DBVSC:H:G&U-H&IDIJ%
M`0)B9*AQKE-E<,7AK4YD/$_ZO(<!UQY^\Q[_`.\^_G/TN\.TD/*-FS1;?;$F
MB15H9G7AX\]`\A_"-,8PO5F'M[K'+KWOW7NB_=A_\SZ^.O\`RP[A_P#>4Q'O
MW7NC`^_=>Z][]U[KWOW7NO>_=>Z][]U[HG?S'ZR[/[#Q7Q_S/5.W<-NW.]/_
M`";ZV[ARVV\SN:+:*Y;;&V,-O/$Y>GQV9J,?DJ:/*(VXXI(HY(PD@1AJ!M[]
MU[I]_P!*7RC_`.\5,1_Z/_:G_P!BOOW7NO?Z4OE'_P!XJ8C_`-'_`+4_^Q7W
M[KW5*'\_KJ+<7R__`)?66Z^^39@^''4^U>WNM.P<GV_BZB#Y%U[Y6@FS&U,)
MM.GZYVLVS,HYS=;O`.U=][XZ5*8ZHVU@K1Y%C74_"O\`AZ'OMK[:\U^[7-L/
M)/)4<,N_W$<CHLLHA33$AD<EV!`HH-!3)QUHT'^4[_+U`)_X=6W4.#R?@AV$
M!_L?^,MGCW0W$0%22!]AZR8_Y-^_>6_Y0-I_[F$7_0/6]G\&/A=NG8G>^:^=
MV"Z+;ND[]ZKZ;VO\?,]O3=N'ZGRVV]B[:Z>V/LG*;SR'7FY,-FLUM?>6])]N
M.T4<U0\E%BY@@.N:6S4,59GN&_$1I^R@S3R)/\@.@_[N^[_,6S^UNS?=FLY(
MDL]@$B;I+;R^)'<WBSRL($D7MDMH-0)(Q)-GA&M;D_\`2E\H_P#O%3$?^C_V
MI_\`8K[5]8E=>_TI?*/_`+Q4Q'_H_P#:G_V*^_=>Z]_I2^4?_>*F(_\`1_[4
M_P#L5]^Z]TVX4=\[\[EZPW+OCIG#];;5V)C>PI*[*Q]I8?>5975^Y<3BL7BZ
M"EQ.,P5!(BDPRR2S/(%0(``2W'NO=&Y]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW5(W_"AC_MU[VW_P"'UT[_`._%P?M/<_`/],O^'K,W[@W_
M`(DKM7_/%?\`_:+)UKO?R'/Y7D?RQ[-7Y-=T8267X^].[BICMW#5U+!)0=K=
ME8IX*Z+$5,-5J%5M#:S/%/D"(WBJYRE)?B?2TJ^.^?[%3_O1]/L'\S]G6?\`
M]^/[S#>U_+A]MN3I@.>MVMSXLBL0UE:."I<%>$\V5BR"BUEI\%=]A$2-%CC5
M41%5$1%"HB*`%55``55`L`.`/:WKAH26)9C5CUR]^ZUU[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$._F/?$7+_`#C^
M,M?\=<5N&AVK3;J[%ZMRVY<[6M-Y:'9VUM[8K/;I.(CAI:L39^?#44L="LBK
M#]RZ&1@@/MF>,RQZ%-,C/RKFGSIP]#GJ;_N]^ZUK[+>X\?N!<P/<R6NWWB0Q
MK2C3S6[Q0ZR66D8D8&0@ZM(.D$TZ-1T]U)L+H?K'9'4'6&!I-M;$Z^V]C]M[
M=Q-)%%'XZ.@A6-JJK>&*$5>4R,^NHJZAEUU%3*\CW9B?;BJJ*%444=1ES;S5
MOG._,E[S9S).UQO=_</+*[$FK,:Z5J3I1!144&BH%48`Z$GW;H.]>]^Z]U[W
?[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
